GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
A New Lens on Alzheimer's: How GE HealthCare's Vizamyl is Revolutionizing Diagnosis and Treatment Monitoring
Imagine peering into the intricate workings of the human brain, not just to see its structure, but to uncover the subtle whispers of a disease that gradually erodes memory, thought, and ultimately, identity. For decades, Alzheimer's disease has presented a formidable challenge, often diagnosed only after significant cognitive decline has set in, and the opportunity for early intervention has diminished. But a recent development, spearheaded by the U.S. Food and Drug Administration (FDA) and GE HealthCare
Finding Inner Peace: Contemplative Meditation for Alzheimer's Caregivers
Caring for a loved one with Alzheimer's disease can be an emotionally and physically exhausting journey. The constant demands, coupled with the heartbreak of witnessing the gradual decline of a once-familiar person, can take a significant toll on caregivers' well-being.
AI Revolution: Decoding Alzheimer’s Before Symptoms Start
For decades, we’ve treated Alzheimer’s like a collapsing building. We usually don’t call the engineers until the roof is already caving in—when memory loss is so severe that it disrupts daily life. The medical criteria from 1984, which set the standard for diagnosis for a long time, were built on this "end-stage" philosophy. By the time we diagnosed the disease, the damage was often irreparable.